Home Newsfeeds Goldman Sachs Maintains Neutral on APA, Lowers Price Target to $41

Goldman Sachs Maintains Neutral on APA, Lowers Price Target to $41

Goldman Sachs maintains APA (NASDAQ:APA) with a Neutral and lowers the price target from $52 to $41.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Goldman Sachs maintains APA (NASDAQ:APA) with a Neutral and lowers the price target from $52 to $41.

RBC Capital Maintains Outperform on Meta Platforms, Raises Price Target to $225

By Benzinga Newsdesk

February 2, 11:24 AM

RBC Capital analyst Brad Erickson maintains Meta Platforms (NASDAQ:META) with a Outperform and raises the price target from $160 to $225.

a.k.a. Brands Holding Corp. Announces Preliminary Unaudited Q1 2023 Results; Sees Q1 Net Sales Of ~$120M Vs Previous Est. $113M-$116M

By Happy Mohamed

April 18, 4:20 PM

Preliminary Unaudited First Quarter 2023 Results Exceed Expectations Company Receives Non-Compliance Notice from NYSE a.k.a. Brands Holding Corp. (NYSE:AKA) (the "Company") today announced

AKA

Benchmark Maintains Buy on Snap, Lowers Price Target to $15

By Benzinga Newsdesk

July 22, 6:54 AM

Benchmark analyst Mark Zgutowicz maintains Snap (NYSE:SNAP) with a Buy and lowers the price target from $20 to $15.

SNAP

Digital Health Tech OptimizeRx’s Acquisition of Medicx Health To Boost Earnings And Market Potential: Analyst

By Vandana Singh

October 12, 1:42 PM

OptimizeRx Corp (NASDAQ: OPRX) agreed to acquire Scottsdale, Arizona-based Healthy Offers Inc, dba Medicx Health,

OPRX

Goldman Sachs Maintains Neutral on APA, Lowers Price Target to $41

Related Posts

RBC Capital Maintains Outperform on Meta Platforms, Raises Price Target to $225

a.k.a. Brands Holding Corp. Announces Preliminary Unaudited Q1 2023 Results; Sees Q1 Net Sales Of ~$120M Vs Previous Est. $113M-$116M

Benchmark Maintains Buy on Snap, Lowers Price Target to $15

Digital Health Tech OptimizeRx’s Acquisition of Medicx Health To Boost Earnings And Market Potential: Analyst